Gapping down
In reaction to disappointing earnings/guidance: VRA -17%, ZGNX -10.2%, (also Zogenix confirms agreement of sale of Zohydro ER Business to Pernix (PTX) for $100 million at closing plus potential milestones of $283.5 million), ERA -6.7%, HABT -6.4%, ONTY -5.1%, WB -4.8%, KOPN -3.4%, SPHS -2.8%, ALOG -0.5%, FGP -0.5%
Select metals/mining stocks trading lower: BHP -3.1%, MT -1.1%, HMY -1.1%, SSRI -0.7%
Select oil/gas related names showing early weakness: STO -1.2%, HAL -1.1%, BP -1.1%, HAL -1.0%
Other news: HDY -28.6% (announces that its common stock began trading today on OTCQX under the symbol HDYN), SXL -5.8% ( announces public offering of 13.5 mln common units ), NBG -3% (cont vol due to Greece/EU bailot), SYN -1.7% (announces that preclinical results supporting the development of SYN-004 will be presented during Digestive Disease Week 2015 in Washington DC on May 16-19), MA -1.3% (attributed to pricing/offering)
Analyst comments: WEN -2.2% (initiated with a Underperform at Credit Suisse), EMC -1.1% (downgraded to Market Perform from Outperform at Wells Fargo), BRFS -0.9% (downgraded to Neutral from Outperform at Credit Suisse)
.
In reaction to disappointing earnings/guidance: VRA -17%, ZGNX -10.2%, (also Zogenix confirms agreement of sale of Zohydro ER Business to Pernix (PTX) for $100 million at closing plus potential milestones of $283.5 million), ERA -6.7%, HABT -6.4%, ONTY -5.1%, WB -4.8%, KOPN -3.4%, SPHS -2.8%, ALOG -0.5%, FGP -0.5%
Select metals/mining stocks trading lower: BHP -3.1%, MT -1.1%, HMY -1.1%, SSRI -0.7%
Select oil/gas related names showing early weakness: STO -1.2%, HAL -1.1%, BP -1.1%, HAL -1.0%
Other news: HDY -28.6% (announces that its common stock began trading today on OTCQX under the symbol HDYN), SXL -5.8% ( announces public offering of 13.5 mln common units ), NBG -3% (cont vol due to Greece/EU bailot), SYN -1.7% (announces that preclinical results supporting the development of SYN-004 will be presented during Digestive Disease Week 2015 in Washington DC on May 16-19), MA -1.3% (attributed to pricing/offering)
Analyst comments: WEN -2.2% (initiated with a Underperform at Credit Suisse), EMC -1.1% (downgraded to Market Perform from Outperform at Wells Fargo), BRFS -0.9% (downgraded to Neutral from Outperform at Credit Suisse)
.